Halberd (Halberd) Days Payable : 87,508.75 (As of Jul. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Halberd Days Payable?

Halberd's average Accounts Payable for the six months ended in Jul. 2023 was $0.48 Mil. Halberd's Cost of Goods Sold for the six months ended in Jul. 2023 was $0.00 Mil. Hence, Halberd's Days Payable for the six months ended in Jul. 2023 was 43,754.38.

The historical rank and industry rank for Halberd's Days Payable or its related term are showing as below:

HALB' s Days Payable Range Over the Past 10 Years
Min: 6570 Med: 47039.38 Max: 87508.75
Current: 87508.75

During the past 3 years, Halberd's highest Days Payable was 87508.75. The lowest was 6570.00. And the median was 47039.38.

HALB's Days Payable is ranked better than
98.9% of 724 companies
in the Biotechnology industry
Industry Median: 148.12 vs HALB: 87508.75

Halberd's Days Payable increased from Jul. 2008 (6,570.00) to Jul. 2023 (87,508.75). It may suggest that Halberd delayed paying its suppliers.

Halberd Days Payable Historical Data

The historical data trend for Halberd's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Halberd Days Payable Chart

Halberd Annual Data

Trend

Jul08

Jul22

Jul23

Days Payable

6,570.00

87,508.75

Halberd Semi-Annual Data
	Jul08	Jul22	Jul23
Days Payable	6,570.00	-	87,508.75

Competitive Comparison of Halberd's Days Payable

For the Biotechnology subindustry, Halberd's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Halberd's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Halberd's Days Payable distribution charts can be found below:

* The bar in red indicates where Halberd's Days Payable falls into.

Halberd Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Halberd's Days Payable for the fiscal year that ended in Jul. 2023 is calculated as

	Days Payable (A: Jul. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Jul. 2022 )	+	Accounts Payable (A: Jul. 2023 ))	/	count )	/	Cost of Goods Sold (A: Jul. 2023 )	*	Days in Period
=	( (0.377	+	0.582)	/	2 )	/	0.002	*	365
=	0.4795					/	0.002	*	365
=	87,508.75

Halberd's Days Payable for the quarter that ended in Jul. 2023 is calculated as:

	Days Payable (Q: Jul. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Jul. 2022 )	+	Accounts Payable (Q: Jul. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Jul. 2023 )	*	Days in Period
=	( (0.377	+	0.582)	/	2 )	/	0.002	*	365 / 2
=	0.4795					/	0.002	*	365 / 2
=	43,754.38

Halberd Days Payable Related Terms

Thank you for viewing the detailed overview of Halberd's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Halberd (Halberd) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halberd Corp (OTCPK:HALB) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

P.O. Box 25, Jackson Center, PA, USA, 16133

Website

https://www.halberdcorporation.com

Halberd Corp is a research-based biotechnology company seeking to discover and develop medical treatments for a range of diseases. The Company's extracorporeal treatment is designed to treat hard-to-cure blood-borne, neurologic and infectious diseases. The Company's patented methodology removes the appropriate bodily fluid from the patient, in a continuous fashion, like dialysis, or in a batch process, like blood sample testing.

Executives

John Christopher Maddox	director, 10 percent owner, officer: President, COO, Treasurer and, other: Interim CFO	10755 VERNON, HUNTINGTON WOODS MI 48070
Mark Sven Lundquist	director, 10 percent owner, officer: CEO, Secretary and Director	24655 TUDOR LANE, FRANKLIN MI 48025
Cocco Nicholas A. Jr.	director	50104 N. JIMMY COURT, CHESTERFIELD MI 48047-1898
Leland Michael Thomas	director	280 LASALLE PLACE, GROSSE POINTE FARMS MI 88236